ArticleEpilepsia open2025
Epilepsy and systemic autoimmune diseases: A bidirectional two-sample Mendelian randomization study.
Article in Epilepsia open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Causal risk and protective factors for rheumatoid arthritis: a comprehensive mendelian randomization systematic review and meta-analysis.Frontiers in genetics · 2026Pooled it
- Epilepsy and systemic autoimmune diseases: A bidirectional two-sample Mendelian randomization study.Epilepsia open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveEpidemiological data indicates that individuals with epilepsy exhibit an elevated susceptibility to autoimmune disorders, and conversely, those with systemic autoimmune diseases (SAD) demonstrate a heightened predisposition to epilepsy. Although an increasing number of publications support this association, the causal direction remains undetermined. This investigation offers evidence supporting a causal relationship between these conditions through a bidirectional two-sample Mendelian randomization (MR) analysis.
methodsBidirectional two-sample MR analyses were performed to investigate the causal relationships and directionality between various epilepsy subtypes and eight SAD. The analysis utilized genome-wide association study (GWAS) summary data for the following conditions: type 1 diabetes, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), rheumatoid arthritis, coeliac disease, multiple sclerosis (MS), ulcerative colitis, and Crohn's disease.
resultsIn this study, causal analyses were performed for different epilepsy subtypes and SAD disorders. In the Inverse-Variance Weighted (IVW) model, the MR study indicated that focal epilepsy increased the risk of IBD [odds ratio (OR): 1.15, confidence interval (CI): 1.02-1.30, p: 0.027] and MS [OR: 1.25, CI: 1.07-1.47, p: 0.004]. Childhood absence epilepsy increased the risk of MS [OR: 0.25, CI: 0.07-0.90, p: 0.034]. Reverse analyses showed that SLE increased the risk of myoclonic epilepsy in adolescents [OR: 1.01, CI: 1.00-1.01, p: 0.042], and IBD [OR: 0.99, CI: 0.99-1.00, p: 0.013], and celiac disease [OR: 0.99, CI: 0.99-1.00, p: 0.021] reduced the risk of generalized epilepsy. The results demonstrated homogeneity, and the MR-Egger directions were concordant. SIGNIFICANCE: This study shows that epilepsy is a causal risk factor for both IBD and MS, providing new insights into the prevention of SAD in people with epilepsy. PLAIN LANGUAGE SUMMARY: This paper employs a bidirectional two-sample MR analysis to investigate the genetic correlation between epilepsy and autoimmune diseases, revealing potential associations between the onset of epilepsy and MS as well as IBD. Further exploration in this area requires support from clinical data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.